Loading organizations...
Loading organizations...
Clinical-stage biopharmaceutical company developing NASH treatments.
89bio has raised $160.0M across 2 funding rounds.
89bio has raised $160.0M in total across 2 funding rounds.
89bio has raised $160.0M in total across 2 funding rounds.
89bio's investors include K2 HealthVentures, Gregory Grunberg, M.D., Anat Naschitz, Tomer Kariv, Derek DiRocco.
89bio has raised $160.0M across 2 funding rounds. Most recently, it raised $100.0M Debt in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 11, 2023 | $100.0M Debt | K2 HealthVentures | |
| Oct 25, 2018 | $60.0M Series A | Gregory Grunberg, M.D., Anat Naschitz | Tomer Kariv, Derek DiRocco |